High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.

Faisal M SanaiAbdullah S AlghamdiAhmad A AfghaniKhalid AlswatAdnan AlZanbagiMosfer N AlghamdiAbdallah AlMousaMohammed AseeriAbdullah M AssiriMohamed A Babatin

Published in: Liver international : official journal of the International Association for the Study of the Liver (2018)

A 12-week regimen of OBV/PTV/r ± DSV with or without RBV is highly effective with a favourable safety profile amongst GT4 and GT1 patients with CKD stages 4-5. SVR12 rates were high regardless of patient characteristics.

Keyphrases

chronic kidney disease
hepatitis c virus
end stage renal disease
case report
early onset
randomized controlled trial
clinical trial
peritoneal dialysis